A transforming growth factor-beta receptor-interacting protein frequently mutated in human ovarian cancer.
Journal
  Cancer research.
Citation
  Cancer Res. 65(15):6526-33
Publication date
  2005 Aug 1
Authors
  Ding W
Tang Q
Espina V
Liotta LA
Mauger DT
Mulder KM
Investigators
  David T. Mauger
Kathleen M. Mulder
Grant agencies
  National Cancer Institute
National Center for Research Resources
Grants
  NCI CA-100239
NCI CA-51452
NCI CA-90765
NCI CA-92889
NCRR M01RR10732
MeSH headings
  Carrier Proteins
Drosophila Proteins
Mutation, Missense
Ovarian Neoplasms
Receptors, Transforming Growth Factor beta
MeSH qualifiers
  genetics
metabolism
Abstract
  Ovarian carcinomas, particularly recurrent forms, are frequently resistant to transforming growth factor-beta (TGF-beta)-mediated growth inhibition. However, mutations in the TGF-beta receptor I and receptor II (TbetaR-I and TbetaR-II) genes have only been reported in a minority of ovarian carcinomas, suggesting that alterations in TGF-beta-signaling components may play an important role in the loss of TGF-beta responsiveness. Using laser-capture microdissection and nested reverse-transcription-PCR, we found that km23, which interacts with the TGF-beta receptor complex, is altered at a high frequency in human ovarian cancer patients. A novel form of km23, missing exon 3 (Deltaexon3-km23), was found in 2 of 19 tumor tissues from patients with ovarian cancer. In addition to this alteration, a stop codon mutation (TAA --> CAC) was detected in two patients. This alteration results in an elongated protein, encoding 107-amino-acid residues (Delta107km23), instead of the wild-type 96-amino-acid form of km23. Furthermore, five missense mutations (T38I, S55G, T56S, I89V, and V90A) were detected in four patients, providing a total alteration rate of 42.1% (8 of 19 cases) in ovarian cancer. No km23 alterations were detected in 15 normal tissues. Such a high alteration rate in ovarian cancer suggests that km23 may play an important role in either TGF-beta resistance or tumor progression in this disease. In keeping with these findings, the functional studies described herein indicate that both the Deltaexon3-km23 and S55G/I89V-km23 mutants displayed a disruption in binding to the dynein intermediate chain in vivo, suggesting a defect in cargo recruitment to the dynein motor complex. In addition, the Deltaexon3-km23 resulted in an inhibition of TGF-beta-dependent transcriptional activation of both the p3TP-lux and activin responsive element reporters. Collectively, our results suggest that km23 alterations found in ovarian cancer patients result in altered dynein motor complex formation and/or aberrant transcriptional regulation by TGF-beta.